BioSpace News Archive

Obesity Action Coalition’s (OAC) latest initiative, Weight of the World, is a global effort designed to link people with obesity through a user-friendly web platform of shared stories about their weight and health journeys.

The Trust for Public Land today announced October 10 is National Walk to a Park Day. This day will bring people together to walk to their nearest park and encourages them to contact local officials to advocate for local parks.

Verastem Oncology (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has approved COPIKTRA™, an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.

The National Association of Chronic Disease Directors CEO John W. Robitscher and Board President Gabriel Kaplan announced today the election of the FY19 Board of Directors as well as the growth of NACDD Headquarters staff.

Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 2018 Cantor Global Healthcare Conference

Syndax Pharmaceuticals Inc., Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from the ongoing ENCORE 601 cohort enrolling non-small cell lung cancer (NSCLC) patients previously treated with both chemotherapy and PD-(L)1 therapy.

Revance Therapeutics, Inc., (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare Conference in New York, NY.

Ionis Pharmaceuticals, Inc. Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced the appointment of two new members to its Board of Directors effective immediately - Dr. Michael Hayden, Killam Professor at the University of British Columbia and the Director of the Translational Laboratory in Genetic Medicine, and Peter N. Reikes, Vice Chairman, Investment Banking Division, Stifel, Nicolaus & Company, Inc.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced a change in leadership with the appointment of James E. Dentzer as President and Chief Executive Officer effective immediately

ImmunoGen, Inc. today announced that the following presentations by Company management at upcoming investor conferences will be webcast: